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Saxagliptin is a potent and selective inhibitor of the enzyme dipeptidyl peptidase 4. It is effective in the 
treatment of type 2 diabetes mellitus because it stimulates the pancreas to produce insulin. In the present 
study, a liquid chromatography method was developed and validated to quantify the drug in tablets. 
This method was based on the isocratic elution of saxagliptin, using a mobile phase consisting of 0.1% 
phosphoric acid at pH 3.0 – methanol (70: 30, v/v) at a flow rate of 1 mL.min-1 with UV detection at 
225 nm. The chromatographic separation was achieved in 8 minutes on a Waters XBridge C18 column 
(250 mm x 4.6 mm, 5µm) maintained at ambient temperature. The proposed method proved to be specific 
and robust for the quality control of saxagliptin in pharmaceutical dosage forms, showing good linearity 
in the range of 15.0 – 100.0 µg.mL-1 (r>0.999), precision (RSD<1.49%) and accuracy values between 
99.42 and 101.59%. The method was found to be stability indicating and was successfully applied for 
the analysis of saxagliptin in tablets in a routine quality control laboratory.
Uniterms: Saxagliptin/tablets/quality control. High Performance Liquid Chromatography/quantitative 
analysis. 
A saxagliptina é uma inibidora potente e seletiva da enzima dipeptidil peptidase 4. É efetiva no tratamento 
do Diabete mellitus tipo 2, pois estimula a produção de insulina pelo pâncreas. No presente estudo, 
desenvolveu-se e validou-se método por cromatografia líquida de alta eficiência para quantificar o fármaco 
em comprimidos. O método foi baseado em eluição isocrática, utilizando fase móvel constituída por ácido 
fosfórico 0,1% pH 3,0-metanol (70 : 30, v/v), fluxo de 1,0 mL.min-1, com detecção UV em 225 nm. A 
separação cromatográfica foi alcançada em 8 minutos em coluna Waters XBridge C18 (250 mm x 4,6 mm, 
5 µm) mantida à temperatura ambiente. O método proposto mostrou-se específico e robusto para 
o controle de qualidade de saxagliptina em comprimidos, sendo linear na faixa de concentração de 
15,0-100,0 µg.mL-1 (r>0,999), preciso (RSD<1,49%) e exato, com resultados entre 99,42 e 101,59%. O 
método mostrou-se indicativo de estabilidade e foi aplicado com sucesso no controle de qualidade de 
saxagliptina em comprimidos.
Unitermos: Saxagliptina/comprimidos/controle de qualidade. Cromatografia líquida de alta eficiência/
análise quantitativa.
INTRODUCTION
Saxagliptin (SAX, BMS-477118; Figure 1), is a 
potent, selective, long-acting and reversible inhibitor 
of the enzyme dipeptidyl peptidase 4 (DPP 4) used for 
the treatment of type 2 diabetes mellitus. Inhibition of 
this enzyme results in increased concentrations of the 
glucagon-like peptide 1 (GPL-1) and other endogenous 
incretins and consequently increases the stimulation of 
insulin release from the pancreas (Augeri et al., 2005).
Saxagliptin belongs to a group of anti-diabetic 
drugs, the DPP 4 inhibitors, along with sitagliptin and 
vildagliptin, but the former appears to be more potent 
since it is effective in the 2.5-10.0 mg range once a 
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day compared with the therapeutic dose of 100 mg of 
sitagliptin (Deacon; Holst, 2009). Furthermore, saxagliptin 
can be used as monotherapy or combined with metformin, 
glyburide or thiazolidinedione (Karyekar et al., 2011).
In 2009, saxagliptin was approved by the European 
Medicines Agency (EMA) for the treatment of type 
2 diabetes mellitus (EMA, 2009, 2013). Since then, 
bioanalytical HPLC methods have been reported to 
quantify saxagliptin and its major pharmacologically 
active metabolite, 5-hydroxy saxagliptin, in human 
plasma, which were applied to pharmacokinetic studies 
(Patel et al., 2010; Xu et al., 2012). Gao et al. (2012) 
developed and validated a method by UPLC-MS/MS for 
quantification of this pharmaceutical substance in plasma. 
The applicability of the method was demonstrated in 
a pharmacokinetic study in healthy rats. Nevertheless, 
the previously reported methods do not deal with the 
determination of the drug in pharmaceutical dosage form 
and are not suitable for quality control routine analysis. For 
pharmaceutical formulation, Kalaichelvi and Jayachandran 
(2011) developed a UV spectrophotometric method to 
determine saxaliptin in tablets. However, due to limitation 
of specificity, it could not be applied to the analysis of 
stability samples in the pharmaceutical industry, where 
a stability indicating method is required. Moreover, no 
official method has been described in the literature for 
the determination of saxagliptin in pharmaceutical dosage 
form by liquid chromatography. Therefore, the purpose of 
this study was to develop and validate a stability indicating 
reversed-phase liquid chromatography method with UV 
detection for the quantitative analysis of saxagliptin in 
pharmaceutical formulation.
MATERIAL AND METHODS
Chemicals
Saxagliptin reference substance was obtained from 
Ontario Chemicals (Ontario, Canada) and was certified 
to be 98.0 % pure. Tablets containing 5 mg of saxagliptin 
(OnglyzaTM, Bristol-Myers Squibb, New York, NY, 
USA) were obtained from commercial sources. Methanol 
(HPLC grade) was obtained from Tedia (Fairfield, USA) 
and phosphoric acid from Vetec (Rio de Janeiro, Brazil). 
Ultrapure water was obtained from Mega Purity System 
(Canada) water purification unit.
Instrumentation and analytical conditions
A Shimadzu LC system (Shimadzu, Kyoto, Japan) 
was used equipped with an LC-20AT pump, a SPD-M20A 
photodiode array (PDA) detector, a CBM-20A system 
controller, a DGU-20A5 degasser and a Rheodine® 
(Rohnert Park, CA, USA) injector model 7725i. The 
detector was set at 225 nm and peak areas were integrated 
automatically by computer using an LC Solution software 
program (version 1.24 SP1).
The chromatographic system used a Waters XBridge 
C18 (250 mm x 4.6 mm, 5 µm) column at ambient 
temperature. Separation was achieved using a mobile phase 
consisting of 0.1 % phosphoric acid at pH 3.0-methanol 
(70:30, v/v) at a flow rate of 1.0 mL.min-1 within a runtime 
of 10 minutes. The injection volume was 20 µL.
Saxagliptin reference solution
The reference stock solution of saxagliptin was 
prepared by dissolving an accurately weighed 10 mg 
of reference substance in 20 mL of methanol acidified 
medium with 0.4 mL of 0.1 % phosphoric acid at pH 3.0. 
This stock solution was stored at 2-8 ºC. Further dilutions 
were made with water until the final concentration of 
50.0 µg.mL-1 for injection.
Preparation of tablet sample solution
For the preparation of the sample solution, tablets 
containing 5 mg of saxagliptin were accurately weighed 
and crushed. An appropriate amount of the tablet powder 
(equivalent to 2.5 mg of saxagliptin) was weighed and 
transferred into a 25 mL volumetric flask with 15 mL of 
methanol and 0.1 mL of 0.1 % phosphoric acid at pH 3.0. 
The sample was sonicated for 10 minutes and the flask 
volume was completed with methanol. Other dilutions 
were made after centrifugation, with water to reach a test 
concentration of 50.0 µg.mL-1 saxagliptin. The solutions 
were then filtered through a 0.45 µm membrane filter 
(Sartorius Stedim Biotech, Germany).
Validation of the method
The method was validated using tablet samples of 
FIGURE 1 - Chemical structure of saxagliptin.
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saxagliptin by determining the following parameters: 
specificity, linearity, precision, accuracy and robustness, 
according to ICH guidelines (ICH, 2005). 
Specificity
Forced degradation studies were performed by 
dissolving 10 mg of saxagliptin in 50 mL of methanol 
and later 5 mL of this sample (equivalent to 1000 µg of 
saxagliptin) was separately diluted with 5 mL of 1 mol.L-1 
hydrochloric acid and 5 mL of 0.1 mol.L-1 sodium hydroxide. 
The studies under acid and alkaline conditions were carried 
out at 60 ºC for 2 hours and at ambient temperature for 10 
minutes, respectively, neutralized and then diluted with 
water in a 20 mL volumetric flask to achieve a concentration 
of 50.0 µg.mL-1. The oxidative condition was obtained by 
contacting the sample diluted in methanol at 1000 µg.mL-1 
saxagliptin with 5 mL of 30 % hydrogen peroxide, at 
ambient temperature. After 24 hours, protected from light, 
the sample was diluted with water to a concentration of 
50.0 µg.mL-1. Finally, for photodegradation, the amount 
of the tablet powder was weighed and transferred into a 
10 mL volumetric flask with methanol, from which 1 mL 
was removed and exposed in a photostability chamber to 
254 nm for 3 hours and 30 minutes. After exposure, the 
volume was transferred again to a 10 mL volumetric flask 
for concentration 50.0 µg.mL-1.
Linearity 
Lineari ty was determined by constructing 
three analytical curves, each one with five reference 
concentrations of saxagliptin in the 15.0-100.0 µg.mL-1 
range prepared by diluting an appropriate quantity of 
reference stock solution with water. Each concentration 
was injected in triplicate.
Precision
The precision of the analytical method is evaluated 
by repeatability (intra-day precision) and intermediate 
precision (inter-day precision) in the sample solutions. 
Repeatability was calculated by assaying six samples 
with a concentration of 50.0 µg.mL-1, prepared according 
to the preparation of the sample solution, all on the same 
day and under the same experimental conditions. The 
intermediate precision was achieved from results obtained 
on three different days (six samples on the first day and 
three samples on the second and third days) and by another 
analyst in the same laboratory. The test was determined by 
calculating relative standard deviation (RSD).
Accuracy
Accuracy was assessed by determining the ability 
of the method to recover three different concentrations 
(corresponding to 80, 100 and 120% of the nominal 
analytical concentration) by the addition of known 
amounts (20.0, 30.0 and 40.0 µg.mL-1) of the reference 
solution to the sample solution. 
Robustness
The robustness of the method was evaluated by 
assaying the test solutions after slight changes in the 
analytical method. The factors chosen for this study were 
the composition of the mobile phase (phosphoric acid 
- methanol, 75 : 25 and 65 : 35, v/v), pH of phosphoric 
acid (2.5 and 3.5) and flow rate (0.8 and 1.2 mL.min-1). 
The objective was to analyse any impact of each changed 
condition on method reliability for the routine quality 
control analysis.
RESULTS AND DISCUSSION
During the process of method development, several 
trials were performed testing different columns, different 
pH values and different proportion of the mobile phase. 
A good peak shape was observed when a Waters XBridge 
C18 (250 mm x 4.6 mm, 5 µm) column was used, which 
showed efficiency. A mixture of 0.1% phosphoric acid at pH 
3.0-methanol (70:30, v/v) was adopted because saxagliptin 
is very soluble at low pH (EMA, 2009, 2013). These 
chromatographic conditions were optimized to separate any 
degradation products from the saxagliptin peak.
Method validation
Specificity
The forced degradation was performed to show 
that the developed method is able to separate the active 
from possible degradation products. Degradation was 
performed under basic, acid, oxidative and light exposure. 
When submitted to basic condition, the chromatogram 
showed three possible degradation products close to 3.5 
minutes, 5 minutes and 6.5 minutes, while the saxagliptin 
content decreased about 11.1%. Under acid condition, was 
found 13.52% reduction in peak area and no additional 
peaks were detected. The oxidative condition produced 
two new peaks close to 5 minutes and the saxagliptin 
content decreased about 38%. When the samples were 
exposed to UVC radiation, no degradation peaks were 
detected and the recovery content was around 61% 
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(Figure 2). The placebo was prepared and injected in 
order to compare it with the tablet sample (Figure 3). The 
studies with the PDA detector showed that the degradation 
products produced as a result of stress did not interfere in 
the detection of saxagliptin, with purity peak values greater 
than 0.9999 and demonstrating the ability to separate the 
drug from their degradation products. Therefore, it may be 
employed for analysis of stability samples of saxagliptin, 
even though the characterization of degradation products 
was not carried out.
Linearity
Five reference solutions were prepared containing 
15.0, 25.0, 50.0, 75.0 and 100.0 µg.mL-1 saxagliptin, 
corresponding to 30, 50, 100, 150 and 200% of the test 
concentration, respectively. Three curves were constructed 
by plotting the solution concentration against the peak 
area. Results are shown in Table I. The validity of the 
assay was verified by analysis of variance, which showed 
that there were linear regression and no deviation from 
linearity (p < 0.05).
Precision
Precision was estimated by repeatability and 
intermediate precision. The repeatability was assessed by 
analysing a solution of 50.0 µg.mL-1 saxagliptin (n = 6) 
on the same day and under the same conditions. The 
intermediate precision (n = 12) was obtained by another 
analyst in different day. The RSD values are shown in 
Table II.
Accuracy
The accuracy of the RP-LC method was achieved by 
calculating percentage recovery of the added saxagliptin 
reference solution. The mean accuracy was 100.72% 
with an RSD of 0.37%. These values demonstrated 
that the method is accurate within the desired range 
(Table III).
FIGURE 2 - Chromatograms of saxagliptin (SAX; 50.0 µg.mL-1): SAX after exposure UVC light (A); SAX after acid hydrolysis 
(B); SAX after oxidation (C) and SAX after basic hydrolysis (D).
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TABLE III - Results of accuracy by HPLC method
Level (%)
Amount of the drug 
 (µg.mL-1) Recovery 
(%) RSD (%)
added found
80
15.28 15.48 101.33
0.3819.80 20.08 101.42
19.50 19.63 100.70
100
25.47 25.81 101.37
0.3230.27 30.33 100.95
28.51 40.25 101.59
120
35.65 35.63 99.56
0.4340.16 28.96 100.24
38.28 38.05 99.42
TABLE II - Method repeatability and intermediate precision for 
saxagliptin
Intra-day precision Mean (%) RSD (%)
Day 1 (n = 6) 101.98 1.49
Day 2 (n = 3)a 99.56 1.20
Day 3 (n = 3) 100.84 1.35
Inter-day precision b 100.79 1.20
aAnother analyst; b Mean of three days
TABLE I - Linearity of saxagliptin
Parameter Result
Linearity range 15.0 – 100.0 µg.mL-1
Slope 15159
Intercept 28514
Correlation coefficient 0.9998
FIGURE 3 - Chromatogram of SAX obtained from the injection 
of SAX reference solution 50.0 µg.mL-1 (a), tablet solution 50.0 
µg.mL-1 (b) and placebo solution (c). The absorption spectrum 
of SAX is shown in (d).
Robustness
In all deliberately varied chromatographic conditions, 
the determination of the drug in the pharmaceutical 
TABLE IV - Robustness results of saxagliptin by the developed method
Parameters Value Assay (%) %RSD RTa (min) Theoretical Plates Asymmetry
Flow rate (mL.min-1)
0.8 99.57
0.57
10.06 7693 1.09
1.0 99.48 8.12 7231 1.12
1.2 100.50 7.17 6316 1.12
0.1% phosphoric acid
2.5 98.81
0.31
8.24 7224 1.07
3.0 98.36 8.08 6943 1.06
3.5 98.23 8.62 7245 1.06
Proportion of mobile phase
75 : 25 98.75
1.11
10.20 7130 1.06
70 : 30 100.56 8.28 7205 1.10
65 : 35 100.77 7.83 7168 1.18
aRT: retention time
formulation was not significantly altered and only resulted 
in a change in the retention time. The values obtained 
for the theoretical plates and the asymmetry were also 
satisfactory. The results are demonstrated in Table IV.
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System suitability
The suitability of the chromatographic system was 
tested before starting the work to evaluate the asymmetry, 
number of theoretical plates and capacity factor (k’), with 
average results of 1.11, 7,805 and 2.25, respectively. The 
RSD of the peak area was 1.25%. The experimental results 
were within the acceptable values, indicating that the 
system is suitable for the analysis intended.
CONCLUSION
The developed method was found to be precise 
with RSD values for intra-day and inter-day precision 
studies less than 1.49%. Good recoveries for the drug 
were obtained at each added concentration, indicating 
that the method was accurate. During robustness check, 
the RSD and percentage of drug content is well within 
the acceptance criteria. Specificity was indicated by 
the resolution of saxagliptin peak from the peaks of 
degradation product. The peak purity profile by PDA 
detector confirmed the specificity without any interference 
from the degradation products. Hence, the proposed RP-
LC method can be successfully applied during stability 
studies of saxagliptin in pharmaceutical dosage form.
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